These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10617087)

  • 1. A short synthesis of troglitazone: an antidiabetic drug for treating insulin resistance.
    Cossy J; Menciu C; Rakotoarisoa H; Kahn PH; Desmurs JR
    Bioorg Med Chem Lett; 1999 Dec; 9(24):3439-40. PubMed ID: 10617087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045.
    Yoshioka T; Aizawa Y; Fujita T; Nakamura K; Sasahara K; Kuwano H; Kinoshita T; Horikoshi H
    Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):2124-5. PubMed ID: 1797433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on compounds with antioxidant activity--development of hypoglycemic agents, troglitazone (CS-045)].
    Yoshioka T; Fujita T
    Yakugaku Zasshi; 1997 Sep; 117(9):597-610. PubMed ID: 9357328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of novel thiazolidinediones.
    Prabhakar C; Madhusudhan G; Sahadev K; Reddy CM; Sarma MR; Reddy GO; Chakrabarti R; Rao CS; Kumar TD; Rajagopalan R
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2725-30. PubMed ID: 9873611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
    Reddy KA; Lohray BB; Bhushan V; Reddy AS; Rao Mamidi NV; Reddy PP; Saibaba V; Reddy NJ; Suryaprakash A; Misra P; Vikramadithyan RK; Rajagopalan R
    J Med Chem; 1999 Aug; 42(17):3265-78. PubMed ID: 10464013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
    Arakawa K; Inamasu M; Matsumoto M; Okumura K; Yasuda K; Akatsuka H; Kawanami S; Watanabe A; Homma K; Saiga Y; Ozeki M; Iijima I
    Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):1984-93. PubMed ID: 9433768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
    Yagi N; Takasu N; Higa S; Ishikawa K; Murakami K; Mimura G
    Horm Metab Res; 1995 Oct; 27(10):439-41. PubMed ID: 8575720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of troglitazone measured by insulin resistance index.
    Nagasaka S; Iwamoto Y; Ishikawa S; Kuzuya T; Saito T
    Lancet; 1997 Jul; 350(9072):184. PubMed ID: 9250189
    [No Abstract]   [Full Text] [Related]  

  • 9. Learning to use troglitazone.
    Riddle MC
    Diabetes Care; 1998 Sep; 21(9):1389-90. PubMed ID: 9727881
    [No Abstract]   [Full Text] [Related]  

  • 10. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
    Willi SM; Kennedy A; Wallace P; Ganaway E; Rogers NL; Garvey WT
    Diabetes; 2002 Oct; 51(10):2895-902. PubMed ID: 12351424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of troglitazone in treating the insulin resistance syndrome.
    Granberry MC; Schneider EF; Fonseca VA
    Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New diabetes drug targets insulin resistance.
    Am J Health Syst Pharm; 1997 Mar; 54(6):623, 625. PubMed ID: 9075488
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.
    Hasegawa I; Murakawa H; Suzuki M; Yamamoto Y; Kurabayashi T; Tanaka K
    Fertil Steril; 1999 Feb; 71(2):323-7. PubMed ID: 9988406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone and small low-density lipoprotein in type 2 diabetes.
    Hirano T; Yoshino G; Kazumi T
    Ann Intern Med; 1998 Jul; 129(2):162-3. PubMed ID: 9669982
    [No Abstract]   [Full Text] [Related]  

  • 16. Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
    Morita H; Oki Y; Ito T; Ohishi H; Suzuki S; Nakamura H
    Diabetes Care; 2001 Apr; 24(4):788-9. PubMed ID: 11315852
    [No Abstract]   [Full Text] [Related]  

  • 17. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats.
    Yoshino K; Takeda N; Sugimoto M; Nakashima K; Okumura S; Hattori J; Sasaki A; Kawachi S; Takami K; Takami R; Yasuda K
    Metabolism; 1999 Nov; 48(11):1418-23. PubMed ID: 10582551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photooxidation of troglitazone, a new antidiabetic drug.
    Fu Y; Sheu C; Fujita T; Foote CS
    Photochem Photobiol; 1996 May; 63(5):615-20. PubMed ID: 8628753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone.
    Spencer CM; Markham A
    Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.